Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma.

Frontiers in immunology - 1 Jan 2024

Wang Xin, Jiang Lang, Zhao Juan, Wu Mi, Xiong Jin, Wu Xiongwen, Weng Xiufang

Abstract excerpt

Background: Mutations commonly occur in cancer cells, arising neoantigen as potential targets for personalized immunotherapy of lung adenocarcinoma (LUAD). However, the substantial heterogeneity observed among individuals and distinct foci within the same patient presents significant challenges in formulating immunotherapy strategies. The aim of the work is to characterize the mutation pattern and identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Computer Simulation

Share to Exome Sequencing

Share to HLA-A2 Antigen

Share to Lung Neoplasms

Share to Peptides

Source

Open in PubMed Open full text

Identifiers

PMID: 39720721
DOI: 10.3389/fimmu.2024.1456209
PMCID: PMC11666526

Genes

NANOGNB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma.PMID 39720721Read ↗

Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and ProspectsSemantic proximity Read ↗

MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine designSemantic proximity Read ↗

Mutation-Derived Neoantigens for Cancer ImmunotherapySemantic proximity Read ↗

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read ↗

The Role of Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancerSemantic proximity Read ↗

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.Semantic proximity Read ↗

ImmuniT Platform for Improved Neoantigen Prediction in Lung CancerSemantic proximity Read ↗

Neoantigens in Cancer Immunotherapy: An Overview with a Focus on Non-small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review)Semantic proximity Read ↗

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.